Jorgen Jelstad Norwegian Journalist Covering ME/CFS
Norwegian journalist Jorgen Jelstad has been all over the Rituximab story. His Invest in ME Conference tweets updated us on recent events, in his “How Important is Rituximab?” blog he talked with researchers about Rituximab’s potential and in his recently blog, “The Drug”, he published a blow-by-blow account of how Rituximab grew to such prominence in the ME/CFS universe. Thanks for allowing Phoenix Rising to publish the story..Here we give a synopsis of the story and of Jorgen’s recent interview with Dr’s. Mella and Fluge.
It turns out that it all began almost 10 years when Anne Katrine, a CFS patient with leukemia, walked into Dr.… Read More
It doesn’t always take a village; sometimes it just takes a committed few to possibly change the future of a disorder; in this case, it may come down to just thirty patients and two researchers in Norway. The news that 2/3rds of CFS patients taking a chemotherapy drug called Rituximab significantly improved in a rigorous, double-blinded placebo controlled trial swept the CFS community immediately and then medical websites.
Rituximab has been a kind of underground hope that’s slowly been getting stronger and stronger over time. Reports suggesting that Rituximab was helping, sometimes REALLY helping, in a small group of patients, began filtering out of Norway about a year and a half ago and Dr.… Read More